BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsConference / presentation

PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026

Open original release

Related news

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

ARWRArrowhead Pharmaceuticals2026-02-24 12:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

APLSApellis Pharmaceuticals2025-11-25 12:00 EST

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

CRNXCrinetics Pharmaceuticals2026-05-22 20:05 EST

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

RCKTRocket Pharmaceuticals2026-01-05 12:00 EST

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

RCKTRocket Pharmaceuticals2025-11-25 12:00 EST

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

PTCTPTC Therapeutics, Inc.2026-05-04 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-02-23 13:00 EST

PTC Therapeutics to Participate at Upcoming Investor Conferences

APLSApellis Pharmaceuticals2026-02-23 12:00 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

BCRXBioCryst Pharmaceuticals2026-04-28 11:00 EST

BioCryst to Present at Upcoming Investor Conferences

View all latest news

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is an RNA-interference company with deep programs in liver, pulmonary, and rare disease targets.

Recent company news

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-06-22 16:33 EST

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

ARWRArrowhead Pharmaceuticals2026-06-18 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Stock data

Close
85.53 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States